There are 2867 resources available
1753P - Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France
Presenter: Sylvie Negrier
Session: Poster session 18
1754P - Association between body mass index (BMI) and anti-PD1/L1 immune checkpoint inhibitor (ICI) outcomes in patients with metastatic urothelial carcinoma (mUC)
Presenter: Soumaya Labidi
Session: Poster session 18
1756P - Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a nationwide, longitudinal, retrospective study in Hungary
Presenter: Anikó Csilla Maraz
Session: Poster session 18
1758P - Characteristics, management and survival outcomes of French patients (pts) with muscle invasive bladder cancer (MIBC) at high risk of recurrence (MIBC-HR): A study based on the COBLAnCE cohort
Presenter: Aldéric FRASLIN
Session: Poster session 18
1759P - Enfortumab vedotin in metastatic urothelial carcinoma: Retrospective multicentre patient cohort
Presenter: Christopher Darr
Session: Poster session 18
1760P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100
Presenter: Jeanny Aragon-Ching
Session: Poster session 18
1761P - Clinicopathological features of FGFR3-mutated upper tract urothelial carcinoma: A genomic database analysis
Presenter: Alessandro Rizzo
Session: Poster session 18
1762P - MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study
Presenter: Mathilde Haberstich
Session: Poster session 18